Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 29,907 | 21,899 | 37,924 | 17,096 | 15,932 |
| Gross Profit | 29,907 | 21,899 | 37,924 | 17,096 | 15,932 |
| Operating Expenses | 222,261 | 169,304 | 185,227 | 142,896 | 136,406 |
| Operating Income | -192,354 | -147,405 | -147,303 | -125,800 | -120,474 |
| Other Income | 28,873 | 6,129 | 5,076 | 2,863 | 2,054 |
| Pre-tax Income | -163,481 | -141,276 | -142,227 | -122,937 | -118,420 |
| Income Tax | 79 | -62 | N/A | N/A | N/A |
| Net Income Continuous | -163,560 | -141,214 | -142,227 | -122,937 | -118,420 |
| Net Income | $-163,560 | $-141,214 | $-142,227 | $-122,937 | $-118,420 |
| EPS Basic Total Ops | -1.63 | -1.41 | -1.49 | -1.34 | -1.34 |
| EPS Basic Continuous Ops | -1.63 | -1.41 | -1.49 | -1.34 | -1.34 |
| EPS Diluted Total Ops | -1.63 | -1.41 | -1.49 | -1.34 | -1.34 |
| EPS Diluted Continuous Ops | -1.63 | -1.41 | -1.49 | -1.34 | -1.34 |
| EBITDA(a) | $-190,115 | $-144,227 | $-145,058 | $-122,213 | $-117,408 |